BPC-157 – 10mg

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide research peptide based on a partial sequence identified in human gastric juice. It is among the most extensively studied research peptides in the preclinical literature, with a research base concentrated largely in work originating from a research group at the University of Zagreb, Croatia, led principally by Predrag Sikiric. This page is a research-reference summary for laboratory professionals sourcing BPC-157 research peptide for in vitro and non-clinical investigation — it is not a guide to human or animal use.

In this reference:

• What Is BPC-157 Research Peptide?
• Proposed Mechanism of Action
• Chemical Identity
• Purity, Storage & Quality
• Research Applications
• Vascular & Major-Vessel-Occlusion Research
• What the Human Evidence Shows
• Compared to Related Research Compounds
• Frequently Asked Questions

What Is BPC-157 Research Peptide?

Research on the BPC-157 research peptide originated from studies of endogenous gastric-protective factors and has since expanded into a broad preclinical literature examining its association with tissue-repair signaling across multiple organ systems. The name “Body Protection Compound-157” reflects its origin as a fragment isolated from a larger gastric-juice protein, BPC, first characterized by Croatian researchers in the 1990s.

Since that original work, BPC-157 has become one of the most frequently cited peptides in published rodent injury-model literature, spanning gastrointestinal, musculoskeletal, dermal, vascular, and central-nervous-system research contexts. The volume of published preclinical data is a primary reason BPC-157 research peptide remains in high demand among laboratories running comparative or mechanistic tissue-repair studies.

It is important for researchers to understand what this body of literature does, and does not, establish. The overwhelming majority of BPC-157 studies are conducted in rodent or in vitro models. As detailed further down this page, controlled human clinical trials are effectively absent from the published record, and study authors themselves frequently note that the compound’s precise molecular target has not been definitively established.

Proposed Mechanism of Action

Study authors have proposed that BPC-157’s reported activity in animal models relates to modulation of growth-factor pathways, including VEGFR2-mediated signaling implicated in angiogenesis, and effects on the nitric-oxide (NO) system. A 2022 peer-reviewed analysis in World Journal of Gastroenterology examined BPC-157’s association with the VEGFR2-Akt-eNOS signaling axis in rodent models of major-vessel occlusion, proposing this pathway as a candidate explanation for the compound’s reported effects on collateral-vessel recruitment following vascular injury (Sikiric et al., 2022 — PMC8793015).

Other proposed mechanisms in the published literature include modulation of the dopaminergic and serotonergic systems, interaction with the prostaglandin pathway, and effects on fibroblast growth factor receptor (FGFR1) signaling relevant to angiogenesis and wound closure. Rodent studies examining the FGFR1 pathway have reported that co-administration of an FGFR1 inhibitor attenuated several of the healing-related measures otherwise associated with the peptide in those models, which authors cite as indirect support for FGFR1 involvement — though this remains one candidate pathway among several proposed, not a confirmed mechanism.

No single receptor or binding target has been isolated and confirmed as this compound’s primary mechanism; the peptide’s activity profile in published models remains, in the authors’ own words, incompletely characterized at the molecular level. Researchers should treat every mechanistic claim in this section as a proposed explanation drawn from a specific published study, not an established pharmacological fact.

Chemical Identity

CAS Number	137525-51-0
Molecular Formula	C62H98N16O22
Molecular Weight	1419.55 g/mol
Sequence Length	15 amino acids (pentadecapeptide)
Appearance	White to off-white lyophilized powder

Purity, Storage & Quality

First Class Science supplies this BPC-157 research peptide vial at 99% purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at our Certificate of Analysis page, listing the specific lot’s purity result, molecular-weight confirmation, and test date.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability; unopened and properly stored, lyophilized peptide is generally stable for extended periods. After reconstitution with bacteriostatic or sterile water, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions, both of which are associated with accelerated peptide degradation in handling literature.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Quality Control Methodology

Each production batch of this BPC-157 research peptide undergoes independent third-party testing before release. High-performance liquid chromatography (HPLC) is used to confirm purity by measuring the proportion of the target peptide relative to any synthesis by-products or degradation fragments in the sample. Mass spectrometry is used separately to confirm molecular identity, verifying that the measured mass of the material matches the expected 1419.55 g/mol molecular weight of BPC-157. Both results are recorded on the batch’s published Certificate of Analysis, allowing researchers to independently verify the identity and purity of the material used in their protocols rather than relying on manufacturer claims alone.

Preparing Solutions for Laboratory Use

Laboratories reconstituting lyophilized BPC-157 research peptide for in vitro assay use typically follow standard peptide-handling practice: the vial is brought to room temperature before opening, and a diluent — commonly reconstitution solution or sterile water for injection (SWFI) — is added slowly down the interior wall of the vial rather than directly onto the lyophilized material, to reduce foaming and mechanical stress on the peptide. The vial is then gently swirled, never shaken, until the powder is fully dissolved.

Stock-solution concentration for a given protocol is calculated by dividing the total peptide mass in the vial by the volume of diluent added — for example, a laboratory targeting a specific milligram-per-milliliter stock concentration for an assay would select a diluent volume accordingly, and record that calculation in their protocol documentation. This page describes general laboratory reconstitution practice for research use and is not a dosing guide for human or animal administration.

Who Sources This Research Peptide

Buyers of this BPC-157 research peptide are university and academic research laboratories, contract research organizations (CROs), and biotechnology R&D teams running in vitro and animal-model studies on tissue-repair and vascular-signaling pathways. First Class Science requires that all research-peptide orders be placed by parties who acknowledge and agree to the research-use-only terms stated on this page prior to purchase.

Institutional buyers frequently request the Certificate of Analysis for a specific lot in advance of purchase for their own internal quality-assurance records, and First Class Science makes this available on request in addition to the standing copy published for each batch.

Research Applications

The published literature on BPC-157 spans several distinct research areas. Each is summarized below strictly as a description of what has been studied in animal and in vitro models — not as a claim about effects in humans.

Gastrointestinal-Protection Research

Animal-model research has examined BPC-157’s association with gastric-mucosal protection and healing measures in chemically-induced ulcer and inflammatory-bowel-disease models, an area representing the compound’s original research context. Rodent studies have reported measures of mucosal-lesion reduction and healing-rate differences relative to control groups in these models.

Tendon, Ligament & Muscle-Repair Research

A substantial body of preclinical research has examined BPC-157’s association with healing-rate and biomechanical-strength measures in tested animal models of tendon, ligament, and muscle injury, including transected and crush-injury models. Several of these studies report measures of fibroblast activity and collagen organization at injury sites in treated versus control animals.

Angiogenesis & Wound-Healing Research

Research has examined BPC-157’s association with new blood-vessel formation (angiogenesis) and accelerated wound-closure measures across skin, corneal, and other soft-tissue injury models in tested animals. This research area overlaps with the vascular-signaling work discussed in the mechanism section above.

CNS & Neuroprotection-Related Research

Separate preclinical research has examined BPC-157’s association with neuroprotective measures in animal models of traumatic brain and spinal-cord injury, and its reported interaction with dopaminergic and serotonergic signaling systems in tested models. This research area remains earlier-stage relative to the gastrointestinal and connective-tissue literature, with fewer independent replications published to date.

Vascular & Major-Vessel-Occlusion Research

A more recent line of published research has focused specifically on BPC-157’s association with recovery measures following major-vessel occlusion. The 2022 World Journal of Gastroenterology paper referenced above examined rodent models of Pringle-maneuver-induced ischemia-reperfusion injury, major-vessel occlusion, and Budd-Chiari-syndrome-like presentations, reporting that BPC-157 administration was associated with resolution of vascular-disturbance measures and improved recovery indicators relative to control groups in these specific animal models (Sikiric et al., World J Gastroenterol, 2022 Jan 7;28(1):23-46; PMID 35125818; DOI 10.3748/wjg.v28.i1.23).

This vascular research thread is mechanistically linked to the angiogenesis findings noted above, with study authors proposing a shared VEGFR2-Akt-eNOS pathway as a candidate explanation across both research areas. As with all findings summarized on this page, these results are specific to the animal models tested and have not been established in controlled human studies.

What the Human Evidence Shows

Researchers evaluating BPC-157 should be aware of an important gap between the animal literature summarized above and the human evidence base. A 2025 systematic review published in the HSS Journal (Vasireddi et al., “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review”) examined the full published literature on BPC-157 in a musculoskeletal research context and found that 35 of the 36 studies identified were preclinical (animal or in vitro) in design. Only one small human study was identified — a retrospective chart review of 12 patients, of whom 7 reported symptom relief lasting more than six months.

The same review reports that no controlled human clinical trials of BPC-157 were found in the published literature, and that no formal human safety data were identified. This is consistent with BPC-157’s regulatory status: it is not an FDA-approved drug, has not completed human clinical trials, and is not evaluated by the FDA for safety or efficacy in humans or animals for any condition.

We include this section because researchers deserve an accurate picture of the evidence base, not just the parts that sound most compelling. The strength of the rodent and in vitro literature on BPC-157 is real and well-documented; the near-total absence of controlled human data is equally real and belongs in the same conversation.

This distinction matters for how findings from this page should be used. A researcher citing BPC-157’s angiogenesis or tendon-repair literature in a grant application, protocol design, or comparative study should characterize those findings accurately as preclinical, animal-model results, rather than implying an established human effect that the published record does not yet support. As more rigorously controlled human research is published, if any, this page will be updated to reflect it.

Compared to Related Research Compounds

BPC-157 is frequently studied alongside, or in combination with, other tissue-repair-associated research peptides. First Class Science supplies several related preparations for researchers running comparative studies:

BPC-157 Capsules – 500mcg supply the same research peptide in an oral-research format rather than lyophilized powder for reconstitution, for laboratories whose protocols call for oral-route administration models.

BPC-157/TB-500 Blend Capsules – 1mg combine BPC-157 with TB-500 (Thymosin Beta-4), another peptide studied in tissue-repair and angiogenesis contexts, for researchers modeling combined-pathway effects.

BPC Wolverine – 10mg/10mg is First Class Science’s branded double-vial BPC-157 preparation — two separate 10mg BPC-157 vials sold as a set, not a blend with any other peptide — for researchers whose protocols call for a larger total BPC-157 quantity per order.

Each of these related preparations carries its own Certificate of Analysis and is subject to the same research-use-only terms described on this page. Laboratories choosing between a lyophilized single-compound vial, an oral-research capsule format, and a pre-blended combination vial typically base that decision on their specific study design: single-compound vials give the most control over exact concentration and combination ratios in a protocol, oral capsule formats are used where a study calls for oral-route rather than reconstituted-solution administration models, and pre-blended vials reduce preparation steps for labs running a fixed, previously-validated combination ratio across multiple replicates.

Common Research Study Designs

Published studies referenced throughout this page typically fall into one of several designs: controlled rodent injury models comparing treated and untreated groups on a defined healing-rate or biomechanical outcome measure; in vitro cell-culture assays examining a specific signaling pathway in isolation; and, far less commonly, small retrospective human chart reviews of the kind discussed in the human-evidence section above. Understanding which design underlies a given finding is important context for interpreting the strength of any individual claim in the literature, since a rodent-model finding and a controlled human trial finding carry very different evidentiary weight.

Frequently Asked Questions

What is the purity of this BPC-157 research peptide?
Every batch is independently verified at 99% purity via third-party HPLC and mass-spectrometry testing, with a Certificate of Analysis published for each lot.

How should BPC-157 research peptide be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is BPC-157 approved for human or animal use?
No. BPC-157 is not an FDA-approved drug and has not completed controlled human clinical trials. It is sold exclusively for in vitro laboratory research and scientific investigation.

How does BPC-157 differ from BPC Wolverine?
BPC Wolverine is First Class Science’s own branded name for BPC-157, supplied as two 10mg vials in one order — it is not a blend with another peptide. This product is the same BPC-157 research peptide in a single 10mg vial, for researchers who need a smaller quantity or prefer to purchase in single-vial units.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date, allowing researchers to independently verify the identity and purity of the specific batch they receive.

Does the published research on BPC-157 include human clinical trials?
No. As detailed in the “What the Human Evidence Shows” section above, a 2025 systematic review found that 35 of 36 published studies on BPC-157 were preclinical, with only one small retrospective human chart review identified and no controlled human clinical trials in the published record.

Can BPC-157 research peptide be shipped internationally?
Shipping availability and any import restrictions for research peptides vary by destination country and are subject to change; researchers should confirm their local import regulations for research-use-only compounds before ordering.

Shipping, Handling & Compliance

This BPC-157 research peptide ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Order tracking, batch-specific documentation requests, and general product questions can be directed to First Class Science customer support, which can confirm current lead times and any destination-specific documentation a receiving institution may require for its own compliance records.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or clinical research contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.